Torsemide comparison with furosemide for management of heart failure (TRANSFORM-HF)

General Information

Age Group




Protocol Number


Background Information

The objective of the TRANSFORM-HF study is to compare the treatment strategy of torsemide versus furosemide on long-term clinical outcomes among patients hospitalized for heart failure. All patients will be followed for a minimum of 12 months.

Offered At

Inova Fairfax Hospital
3300 Gallows Road
Falls Church, VA 22042

Principal Investigator

Mitchell Psotka, MD, PhD

Eligibility Information

  • Patient hospitalized (≥ 24 hours or over a change in calendar date) with worsening of chronic heart failure, or new diagnosis of heart failure AND meets 1 of the following criteria:
    • Has a left ventricular ejection fraction (EF) ≤ 40% within 24 months prior to and including index hospitalization by any method (with most recent value used to determine eligibility)
    • Has an elevated natriuretic peptide level (either NT-pro-B-type natriuretic peptide or B-type natriuretic peptide) during index hospitalization as measured by local laboratory
  • Plan for a daily outpatient oral loop diuretic regimen upon hospital discharge with anticipated need for long-term loop diuretic use
  • ≥ 18 years of age
  • Signed informed consent

Ineligibility Information

  • End-stage renal disease requiring dialysis therapy
  • Inability or unwillingness to comply with the study requirements
  • History of heart transplant or actively listed for heart transplant
  • Implanted left ventricular assist device or implant anticipated < 3 months
  • Pregnant or nursing women or women who are trying to conceive
  • Malignancy or other non-cardiac condition limiting life expectancy to < 12 months
  • Known hypersensitivity to furosemide, torsemide, or related agents

For additional information, please visit: